The US Food and Drug Administration (FDA) has issued a warning letter to L'Oréal for gene, stem cell and skin regeneration claims associated with Lancôme products. According to the FDA, the claims used for the 10 identified products can be interpreted as altering the structure and function of the skin and, therefore, classify the products as drugs.

The FDA advised the company to review claims associated with these products to ensure that they comply with the Food, Drug, and Cosmetic Act. L'Oréal has 15 days to respond to the letter with its plan of action, without which injunctions and seizures can take place.